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ABSTRACT: A solid understanding of the mechanisms governing
ligand binding is crucial for rational design of therapeutics
targeting the dopamine D2 receptor (D2R). Here, we use G
protein-coupled inward rectifier potassium (GIRK) channel
activation in Xenopus oocytes to measure the kinetics of D2R
antagonism by a series of aripiprazole analogues, as well as the
recovery of dopamine (DA) responsivity upon washout. The
aripiprazole analogues comprise an orthosteric and a secondary
pharmacophore and differ by the length of the saturated carbon
linker joining these two pharmacophores. Two compounds
containing 3- and 5-carbon linkers allowed for a similar extent of
recovery from antagonism in the presence of 1 or 100 μM DA
(>25 and >90% of control, respectively), whereas recovery was less prominent (∼20%) upon washout of the 4-carbon linker
compound, SV-III-130, both with 1 and 100 μM DA. Prolonging the coincubation time with SV-III-130 further diminished recovery.
Curve-shift experiments were consistent with competition between SV-III-130 and DA. Two mutations in the secondary binding
pocket (V91A and E95A) of D2R decreased antagonistic potency and increased recovery from SV-III-130 antagonism, whereas a
third mutation (L94A) only increased recovery. Our results suggest that the secondary binding pocket influences recovery from
inhibition by the studied aripiprazole analogues. We propose a mechanism, supported by in silico modeling, whereby SV-III-130
initially binds reversibly to the D2R, after which the drug-receptor complex undergoes a slow transition to a second ligand-bound
state, which is dependent on secondary binding pocket integrity and irreversible during the time frame of our experiments.
KEYWORDS: drug kinetics, competitive binding, antipsychotics, PET scan, molecular dynamics simulation, Xenopus oocytes, arrestin,
HEK cells
■ INTRODUCTION
The dopamine D2 receptor (D2R) is a G protein-coupled
receptor (GPCR) and an important pharmaceutical target.
D2R antagonism or weak partial agonism is the common
denominator of antipsychotic drugs, and D2R agonism is a
mainstay of Parkinson’s disease treatment.1−4 The time course
of receptor occupancy has been suggested to have an
important impact on the clinical properties of therapeutic
ligands, including antipsychotics, where transient rather than
continuous D2R occupancy may be associated with a more
favorable profile in terms of extrapyramidal side effects.5
Ligand binding kinetics is presumed to play an important role
in determining the time course of occupancy at the target
receptor.6,7 For example, the action of angiotensin-1 receptor
antagonists is prolonged by their long-lasting, induced-fit
binding to their target receptor, reflected by insurmountable
antagonism in in vitro experiments.8 Insurmountable antago-
nism is characterized by a decrease in the maximal agonist-
induced response, which cannot be overcome by increasing the
concentration of agonist.8
Similarly, differences in dissociation9 or association
kinetics10 between antipsychotics have been linked to their
differential side-effect profiles, although this remains a matter
of debate.11 Receptor binding kinetics has also been predicted
to be an important determinant of positron emission
tomography (PET) tracer characteristics, such as sensitivity
to endogenous neurotransmitter release.12
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The recently reported D2R crystal structure reveals a deep
orthosteric binding pocket, situated in the plane of the cell
membrane between transmembrane segments 3, 5, and 6, as
well as a secondary binding pocket, located more extracellularly
and mainly comprising residues from transmembrane segment
2 and extracellular loop 1.13 In search of GPCR ligands with
beneficial pharmacological properties and enhanced selectivity,
attention has been drawn to bivalent ligands, consisting of two
distinct pharmacophores targeting both the orthosteric and the
secondary binding pocket.14 To facilitate parallel engagement
of both pockets, the orthosteric- and secondary pharmaco-
phores are covalently joined by a linker, the length of which
has been found to be critical.15 At the D2R, ligand interactions
with the secondary binding pocket have been reported to
confer selectivity over the closely related D3R and, in some
cases, to impart signaling bias or allosteric properties.16,17 In
particular, a cluster of residues in transmembrane segment 2,
including V91, L94, and E95, has been found to mediate
important contacts between the ligand and the secondary
binding pocket.18−20
A series of candidate PET radiotracers, designed to
selectively target D2R, were derived from the scaffold of the
clinically used antipsychotic, aripiprazole. These compounds
are composed of an orthosteric 2-methoxyphenylpiperazine
pharmacophore and a secondary dihydroquinolinone pharma-
cophore, linked by alkyl chains of varying length.15 SWR-1-8,
SV-III-130, and SWR-1-14 contain chains of 3, 4, and 5 carbon
atoms, respectively (Figure 1A), resulting in different distances
Figure 1. Structures, potencies, recovery from antagonism, and binding kinetics of SWR-1-8, SV-III-130, and SWR-1-14 at the D2R. A) Structures
of SWR-1-8, SV-III-130, and SWR-1-14. B) Concentration−response relationship for DA-induced GIRK activation in oocytes coexpressing D2R,
RGS4, and GIRK1/4 channels (EC50 = 33 nM; n = 4). C) Concentration−response curves for the inhibition of the GIRK response to 100 nM DA
by SWR-1-8 (n = 3), SV-III-130 (n = 3), and SWR-1-14 (n = 3). D) Recovery of D2R-mediated GIRK activation by DA after antagonism by SWR-
1-8 (n = 8 for 1 μM DA and n = 5 for 100 μM DA), SV-III-130 (n = 11 for 1 μM DA and n = 12 for 100 μM DA), and SWR-1-14 (n = 7 for 1 μM
DA and n = 4 for 100 μM DA). Graphs show mean GIRK current traces normalized to the maximal response evoked by 1 μM DA (40 s), followed
by 30 μM SWR-1-8 or SWR-1-14 or 1 μM SV-III-130 coapplied with 1 μM DA (125 s) and finally reversed by 1 μM (thick dotted line) or 100 μM
(thick solid line) DA (400 s). Thin lines indicate SEM. E) Extent of recovery from antagonism following application of 1 or 100 μM DA (data from
experiments shown in panel D). F) Rate of recovery from antagonism following application of 1 or 100 μM DA (data from experiments shown in
panel D). G) Observed rates of GIRK response decay, kobs, upon application of varying concentrations of antagonist in the presence of 100 nM DA
during 125 s; n = 3−7. Data shown are means ± SEM *; p < 0.05, ***; p < 0.001, and ****; p < 0.0001, Student’s t test.
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and relative orientations between the two pharmacophores.
SV-III-130 was found to be ∼20-fold more potent at the D2R
and ∼40-fold more selective for the D2R over D3R compared
to SWR-1-8 and SWR-1-14, demonstrating the crucial impact
of linker length on D2R affinity. [
11C]-SV-III-130 has
subsequently been used as a D2R selective PET tracer in
nonhuman primates.21
While important roles of the D2R secondary binding pocket
in mediating subtype selectivity and allosteric effects have been
described, the putative involvement of this pocket in the
reversibility of antagonism has not been examined. Here, we
compared the binding kinetics, reversibility, and surmount-
ability of the three aripiprazole analogues and examined the
role of the secondary binding pocket in determining these
characteristics. To this end, we used a G protein-coupled
inward-rectifying potassium (GIRK) channel assay as a time-
resolved readout of D2R occupancy by dopamine (DA)
22,23
and developed a mechanistic model, supported by molecular
dynamics simulations, explaining our observations.
■ RESULTS AND DISCUSSION
Role of Linker Length in Determining Potency,
Kinetics, and Surmountability of Antagonism. To
determine the influence of linker length on the kinetics,
reversibility, and surmountability of D2R antagonism, we
studied the properties of the three aripiprazole analogues,
SWR-1-8, SV-III-130, and SWR-1-14, in antagonizing DA-
evoked GIRK activation in Xenopus oocytes coexpressing D2R
with GIRK1/4 channels and RGS4 (Figure 1A, B). SV-III-130
was more potent compared to SWR-1-8 and SWR-1-14
(Figure 1C; Table 1). The Ki values derived from these
experiments were in relative agreement with previous Ki data
from [125I]-IABN radioligand binding experiments (SWR-1-8;
4.8 ± 0.9 nM, SV-III-130; 0.22 ± 0.01 nM, and SWR-1-14; 7.3
± 1.3 nM;15). Ligand-induced GIRK channel block was
observed to be <10% in all cases, as determined by application
of 30 μM SWR-1-8, SWR-1-14, and SV-III-130 to oocytes
expressing GIRK channels in the absence of D2R (Supple-
mentary Figure S1). Previous investigations of SV-III-130 at
the D2R reported partial agonism in an adenylate cyclase
inhibition assay but antagonism in GIRK activation and
ERK1/2 assays.16 In our hands, weak partial agonism at the
D2R in the GIRK activation assay was observed for SV-III-130
(6.6% of the response to 1 μM DA) but not for SWR-1-8 and
SWR-1-14, which behaved as antagonists/inverse agonists
(Supplementary Figure S2).
Reversibility of D2R antagonism was evaluated using a
protocol consisting of three steps: (i) a baseline response
evoked by a maximally effective concentration (1 μM) of DA,
(ii) antagonism of this response by 30 μM of SWR-1-8/SWR-
1-14 or 1 μM SV-III-130, and (iii) recovery of the response
upon washout of the antagonist ligand in the presence of 1 or
100 μM DA. The GIRK response is essentially saturated at 1
μM DA (Figure 1B). Therefore, any additional increase in
response recovery with 100 μM DA should be an effect of
increased competition with antagonist ligand which remains
dissolved in the membrane and/or interior of the cell following
washout, as has been reported to occur for some lipophilic
compounds.22−24 For SWR-1-8, SV-III-130, and SWR-1-14, a
response recovery fraction of 0.2 to 0.4 was observed when
using 1 μM DA in the recovery phase, while increasing the DA
concentration during the recovery phase to 100 μM
Table 1. Binding Kinetics and Affinity Estimates of Ligands at the D2R WT
a
receptor ligand koff (s
−1) kon (s
−1 × M−1) pKd pKi
D2R WT SWR-1-8 0.017 ± 0.002 (5) 3.4 ± 0.4 × 105 (3−6) 7.30 ± 0.04 8.01 ± 0.18 (3)
D2R WT SV-III-130 0.007 ± 0.001 (11) 8.6 ± 0.5 × 105 (3−6) 8.09 ± 0.04 8.57 ± 0.05 (3)
D2R WT SWR-1-14 0.021 ± 0.002 (4) 3.0 ± 0.4 × 105 (4−7) 7.15 ± 0.04 7.70 ± 0.13 (3)
akoff values were calculated from response recovery t1/2 as koff = ln (2)/t1/2. See the Methods section for derivation of kon. pKd was calculated from
the koff and kon estimates as Kd = koff/kon, while pKi was calculated from the IC50 for GIRK channel inhibition using the Cheng−Prusoff equation,25
assuming a Kd of DA equaling its EC50 for GIRK activation in our assay; i.e., 33 nM. The number of oocytes is shown in parentheses; for kon, this
corresponds to the number of oocytes for each data point (see Figure 1G). Data shown are means ± SEM.
Figure 2. Curve-shift GIRK activation assay of D2R antagonism upon coapplication of SV-III-130 and DA. A) Assay principles; 1 μM DA elicits a
full agonist response (left, red arrow). The subsequent response amplitude in the presence of variable concentrations of SV-III-130 and DA,
following 500 s coapplication (right, green arrow), was normalized to the control response elicited by 1 μM DA. In the example shown, 1 μM SV-
III-130 coapplied with 100 μM DA; n = 3 oocytes. Thick lines represent mean normalized currents, whereas thin lines indicate SEM. B) Current
amplitude at the end of the 500 s coapplication period, normalized to the instantaneous maximum response amplitude in the same oocyte and
plotted against DA concentration, for varying concentrations of SV-III-130 or control. n = 3−7 oocytes per data point. Data shown are means ±
SEM.
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significantly increased the response recovery following SWR-1-
8 and SWR-1-14 application to about 0.9 to 1.0 (Figure 1D,
E). Conversely, recovery from SV-III-130-induced antagonism
was about 0.2 under both conditions (Figure 1D, E), indicative
of insurmountable behavior. The response recovery kinetics in
the presence of 100 μM DA, which we previously used as a
measure of antagonist dissociation rate (koff
23), was swift for
SWR-1-8 and SWR-1-14 but slower for SV-III-130 (Figure 1F;
Table 1). Response recovery kinetics was similar at 1 μM and
100 μM DA for SWR-1-8 and SV-III-130 but more rapid at
100 μM compared to 1 μM DA for SWR-1-14 (Figure 1F).
To estimate compound association rate constants (kons), we
employed our previously published strategy,23 using the decay
rate of the DA-evoked GIRK current at different concen-
Figure 3. Potencies, recovery from antagonism, and binding kinetics of SV-III-130 at the V91A, L94A, and E95A mutant D2R. A) DA potency at
V91A (EC50 = 21 nM, n = 3−4), L94A (EC50 = 41 nM, n = 3−7), E95A (EC50 = 15 nM, n = 3−4), W100A (EC50 = 323 nM, n = 3), and WT
(EC50 = 33 nM, n = 4) D2R. B) SV-III-130 potency at the V91A (n = 4), L94A (n = 3), E95A (n = 7), and W100A (n = 3) D2R. C) Recovery of
activation by DA at the V91A (n = 3 for 1 μM DA and n = 4 for 100 μM DA), L94A (n = 13 for 1 μM DA and n = 13 for 100 μM DA), E95A (n =
5 for 1 μM DA and n = 3 for 100 μM DA), and W100A (n = 4 for 10 μM DA and n = 4 for 300 μM DA) mutant D2R following antagonism by SV-
III-130. GIRK current traces normalized to the maximal response evoked by 1 μM (10 μM for W100A) DA. Thick lines represent mean normalized
currents, whereas thin lines indicate SEM. D) Extent of recovery upon application of 1 or 100 μM (10 and 300 μM for W100A) DA following
antagonism by 30 μM (V91A and E95A), 3 μM (W100A), and 1 μM SV-III-130 (L94A; data from experiments shown in panel C). E) Rate of
recovery following application of 1 or 100 μM DA (10 and 300 μM for W100A; data from experiments shown in panel C). F) Observed association
rates, kobs, which allowed for calculation of association rates for SV-III-130 at the V91A, L94A, and E95A D2R. n = 3−7. G) Clustering of kinetic Kd
relative to Ki for SWR-1-8, SWR-1-14, and SV-III-130 at the WT receptor and SV-III-130 at the V91A, L94A, and E95A mutant receptors, as
indicated. Data shown are means ± SEM *; p < 0.05, **; p < 0.01, and ***; p < 0.001, Student’s t test.
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trations of antagonist as a proxy measure of the antagonist
binding rate. Plotting the observed rates of inhibition of the
current response to DA against varying concentrations of
competing ligand suggested a more rapid kon of SV-III-130 at
the D2R, compared to SWR-1-8 and SWR-1-14 which
exhibited similar kons (Figure 1G; Table 1).
SV-III-130 Behaves Competitively When Coapplied
with Different Concentrations of DA. The lack of
increased response recovery from SV-III-130-mediated antag-
onism in the face of increased concentrations of DA could be
indicative of a noncompetitive or possibly allosteric binding
mechanism. To further evaluate this mechanism, we performed
a curve-shift assay to test whether SV-III-130 and DA compete
for binding to the D2R when the two ligands are coapplied.
First, 1 μM DA was applied to each cell to elicit a full agonist
response which could then be compared to the pseudosteady-
state response elicited by 10 nM to 100 μM DA coapplied with
varying concentrations of SV-III-130, or vehicle, after 500 s
coapplication (Figure 2A). The DA concentration−response
curve was progressively right-shifted with increasing concen-
trations of SV-III-130 without any appreciable effect on the
maximal response (Figure 2B), consistent with competition
between DA and SV-III-130 for D2R binding. Thus, SV-III-130
displayed differential behavior (i.e., insurmountable vs
competitive) after first being bound to D2R and then washed
out/competed with DA (Figure 1D, E), compared to when
coapplied with DA without prior D2R binding (Figure 2).
GIRK currents are known to demonstrate a time-dependent
decrease due to alterations of intracellular sodium levels during
prolonged recording protocols.26 The effect of this rundown is
evident in Figure 2B, where the GIRK current response at the
end of the 500 s coapplication period is ∼60% of the
instantaneous response to 1 μM DA.
Insurmountability of SV-III-130 Antagonism Depends
on the D2R Secondary Binding Pocket. The high potency
of SV-III-130 antagonism at the D2R and the insurmountability
of this antagonism, as observed during the recovery phase
when washing out the ligand in the presence of 1 or 100 μM
DA (see Figure 1), likely arise from interactions between the
secondary pharmacophore and the secondary binding pocket,
given the differential behavior of both SWR-1-8 and SWR-1-
14. Previous investigations suggested a crucial role for residues
V91, L94, and E95 in contacting the secondary pharmacophore
of bivalent D2R ligands, including SV-III-130.
16,19 In addition,
W100A in extracellular loop 1 is located at the extracellular
boundary of the secondary binding pocket and has been shown
to affect bivalent ligand affinity and to adopt different
conformations depending on the nature of the bound
ligand.13,27 To investigate the role of the secondary binding
pocket in shaping SV-III-130 binding kinetics and insurmount-
ability, V91, L94, E95, and W100 were individually mutated to
alanine. First, we validated the expression of the D2R mutants
by immunoblot experiments. Anti-D2R antibodies detected a
broad protein band at 80−100 kDa (Supplementary Figure
S3), corresponding to the expected size of fully glycosylated
D2R, as previously reported.
28,29 Importantly, this immunor-
eactive band was absent in striatal membranes from D2R
−/−
mice and in total membranes from uninjected oocytes
(Supplementary Figure S3), thus indicating the specificity of
the antibody used. Overall, these results indicated that WT
D2R, V91A, L94A, E95A, and W100A receptors were properly
expressed in oocytes.
Next, we assessed the surmountability of SV-III-130 at the
D2R mutants in oocytes. In the GIRK activation assay, the DA
potencies were similar for the WT and L94A mutant D2R and
slightly higher for the V91A and E95A mutants (Figure 3A). In
contrast to the other mutant receptors, the potency of DA at
W100A was markedly reduced by about 10-fold compared to
WT (Figure 3A). This probably reflects a loss of DA affinity as
the Western blot experiments indicated relatively similar
expression of W100A, WT D2R, and the other D2R mutants
(Supplementary Figure S3). Further supporting a link between
functional DA potency in our GIRK assay and DA binding
affinity, we have previously shown that there is little or no
receptor reserve under our assay conditions.23 Furthermore,
the E95A and L94A mutants were shown to express at similar
levels as WT and showed insignificant changes in DA potency
in a previous study,18 while alanine mutation of the interaction
partner of W100A, I184, significantly reduced DA potency
despite similar expression. In order to achieve similar receptor
occupancies by DA, we used 1 μM instead of 100 nM DA for
constructing concentration−response curves for SV-III-130-
mediated inhibition at the W100A mutant (Figure 3B) and 10
instead of 1 μM DA to elicit the baseline response when
studying the W100A mutant in response recovery experiments
(Figure 3C).
The inhibitory potency (corrected for differences in DA
potency and expressed as Ki) of SV-III-130 was decreased 9-
fold for V91A and W100A and 4-fold for E95A mutant D2R
(Figure 3B and Table 2). In contrast, SV-III-130 was slightly
more potent at the L94A mutant receptor (about 2-fold)
compared to WT D2R (Figure 3B and Table 2). Partial agonist
activity of SV-III-130 was lost at the V91A mutant but retained
at the L94A and E95A mutants (Supplementary Figure S4).
Response recovery experiments (employing the same
protocol as in Figure 1D) with SV-III-130 using 1 μM (10
μM with W100A) DA in the recovery phase demonstrated an
increased recovery at V91A, L94A, E95A, and W100A mutant
D2R as compared to WT D2R (Figure 3C, D). When 100 μM
(300 μM with W100A) DA was used in the recovery phase, the
Table 2. Binding Kinetics and Affinity Estimates of SV-III-130 at D2R Secondary Binding Pocket Mutants
a
receptor ligand koff (s
−1) kon (s
−1 × M−1) pKd pKi
D2R V91A SV-III-130 0.066 ± 0.005 (4) 4.9 ± 0.4 × 105 (4−5) 6.87 ± 0.05 7.63 ± 0.16 (4)
D2R L94A SV-III-130 0.007 ± 0.001 (13) 8.9 ± 0.6 × 105 (3−7) 8.10 ± 0.05 8.95 ± 0.17 (3)
D2R E95A SV-III-130 0.022 ± 0.005 (3) 3.3 ± 0.4 × 105 (3−4) 7.18 ± 0.05 7.97 ± 0.13 (7)
D2R W100A SV-III-130 0.010 ± 0.001 (4) n.d. n.d. 7.63 ± 0.07 (3)
akoff values were calculated from response recovery t1/2 as koff = ln (2)/t1/2. See Methods section for derivation of kon. pKd was calculated from the
koff and kon estimates as Kd = koff/kon, while pKi was calculated from the IC50 for GIRK channel inhibition using the Cheng−Prusoff equation,25
assuming the Kd of DA at the various mutants to equal the corresponding EC50 for GIRK activation (see the legend of Figure 3A). Number of
oocytes in parentheses; for kon, this corresponds to the number of oocytes for each data point (see Figure 3F). Data shown are means ± SEM. n.d.,
not determined.
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extent of recovery at the four D2R mutants increased further,
suggesting surmountable antagonism by SV-III-130 at these
mutants (Figure 3C, D). Accelerated SV-III-130 recovery
kinetics was observed with 1 μM and 100 μM DA for the
V91A and E95A mutant D2R and with 10 and 300 μM DA for
the W100A mutant, whereas for the L94A mutant, the time to
half-maximal recovery was similar to that observed for WT
D2R (Figure 3E). kon and kinetic Kd estimates for SV-III-130 at
the V91A and E95A mutants were lower than at the WT
receptor, while kon and kinetic Kd appeared similar at the L94A
mutant and WT D2R (Figure 3F, G; Table 2). The
preservation of SV-III-130 kon at the L94A mutant suggests
that a high kon, which may affect ligand competition by causing
rapid rebinding to the receptor,10 is not sufficient to explain
the insurmountable antagonism of SV-III-130 at the WT
receptor.
Kinetic Binding Models Support an Induced-Fit
Binding Mode of SV-III-130 at the D2R. The distinct
extents of recovery from antagonism and differing association
and dissociation rate constants of SWR-1-8, SWR-1-14, and
SV-III-130 at the D2R indicate differential binding modes.
Based on the demonstrated surmountability of SWR-1-8 and
SWR-1-14 antagonism at the WT D2R in the response
recovery experiments (Figure 1D, E), a three-state binding
Figure 4. Simulations of three- and four-state ligand binding at a receptor. A) Scheme depicting a surmountable antagonist ligand (L) binding to
the receptor (R), in competition with the agonist (A; DA). B) Scheme depicting induced-fit insurmountable antagonist ligand binding, where RL*
represents an irreversibly bound antagonist ligand. C, D, E) Simulation of response recovery from antagonism by SWR-1-8 (C), SV-III-130 (D),
and SWR-1-14 (E) at WT D2R, with 1 or 100 μM DA during the recovery phase. The response is assumed to be proportional to the fraction of the
agonist-bound state; RA. F) Simulated recovery of WT D2R activation by DA after prolonged, 400-s antagonism with SV-III-130. G) Experimental
recovery of WT D2R activation by DA after prolonged, 400-s antagonism with SV-III-130. H) Simulated curve-shift assay with SV-III-130 at WT
D2R, plotting the RA fraction after 500 s simulation time for different concentrations of DA and SV-III-130, as indicated. I) Simulated
concentration−response curves for SV-III-130 antagonism at WT and L94A mutant D2R. “Normalized response” corresponds to the RA fraction
after 100 s of simulation time, in the presence of 100 nM DA and varying concentrations of SV-III-130, as indicated. The L94A mutant was
simulated by removing the fourth state, RL*, from the model. J) Simulation of response recovery from antagonism by SV-III-130 at the L94A
mutant D2R. As in I), the three-state model is employed, using kinetic data for SV-III-130 from the L94A mutant. Simulations of SWR-1-8 (C;
kon(RL) = 340 M
−1 s−1, koff(RL) = 0.017 s
−1), SV-III-130 (D; kon(RL) = 860 M
−1 s−1, koff(RL) = 0.007 s
−1, kon(RL*) = 0.01 s
−1), and SWR-1-14 (E; kon(RL)
= 300 M−1 s−1, koff(RL) = 0.021 s
−1) at WT D2R were conducted in the presence of 1 or 100 μM DA as agonist. kon(A) = 5 × 10
6 M−1 s−1 and koff(A) =
0.17 s−1 for all simulations at WT D2R. Parameters for the three-state model of SV-III-130 interaction at D2R L94A; kon(RL) = 890 M
−1 s−1, koff(RL) =
0.007/s, kon(A) = 5 × 10
6 M−1 s−1, and koff(A) = 0.21/s. koff(A) = was adjusted as necessary to yield a Kd corresponding to the DA EC50 at D2R L94A.
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model including unbound receptor (R), agonist-bound
receptor (RA), and ligand-bound receptor (RL) was
constructed using the experimentally determined kon and koff
rate constants (Figure 4A; eq 1 in the Methods section). To
account for lipophilic accumulation in the cell membrane,24 a
residual ligand fraction of 2% was assumed throughout the
response recovery phase. Modeling of the low extent of
recovery from and insurmountable nature of SV-III-130
antagonism required the incorporation of an irreversible,
second ligand-bound state (RL*; Figure 4B; eq 2 in the
Methods section).
Figure 5. Structural impact of L94A mutation on SV-III-130. A) The most populated SV-III-130 binding mode in the D2R WT (blue) and the
L94A (orange) receptors. Upon L94A mutation, the ligand translates toward transmembrane segment 2 as indicated by the yellow arrows. Despite
translation in the L94A mutant, SV-III-130 is primarily sandwiched by W100 and I184 similar to the WT complex. B) Comparison of the position
of W100 between the WT and L94A receptors in terms of distance between Cα atoms of W100 and L/A94, as well as the position of the W100
side chain center of mass in the z-dimension (perpendicular to the membrane). Both values are significantly different between the WT and the
L94A receptors. C) Representative ligand binding mode in the WT receptor with W100 adopting a low z value (putative RL complex). D)
Representative ligand binding mode in the L94A mutant receptor with W100 adopting a low z value (putative RL complex). E, F) Ligand binding
modes in the WT receptor in which W100 adopts higher z values and stacks on top of the ligand (potentially leading to RL* complexes). In C−F),
the position of the center of mass of the W100 side chain (red circle) in the z-dimension (perpendicular to the membrane) is highlighted. **; p <
0.01, Mann−Whitney U test.
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Assuming RA to be proportional to the experimentally
observed GIRK response, simulation of the experimental
response recovery data presented in Figure 1C for SWR-1-8
and SWR-1-14 using the three-state binding model recapitu-
lated the 1 μM DA activation and blocking phases and
demonstrated an increase in the extent of response recovery
with increasing DA concentration (1 versus 100 μM DA;
Figure 4C, E). For SV-III-130, the corresponding simulation
using the extended four-state binding model recapitulated the
experimental extent of recovery for both 1 and 100 μM of DA
during the response recovery phase (Figure 4D). The four-
state model (Figure 4B) may be thought of as modeling
induced-fit binding and implies a time-dependence for SV-III-
130 antagonism of the D2R, with a transition from RL to RL*
defined by the fraction 1−1/(et*0.01), where t is time in
seconds. The simulations predicted a RL-RL* transition of
∼98% when SV-III-130 application was prolonged from 125 to
400 s (Figure 4F). In agreement, in vitro experiments revealed
a virtual elimination of response recovery following application
of SV-III-130 during 400 s (Figure 4G). The four-state model
also recapitulated the competitive behavior of SV-III-130 when
coapplied (without prior occupancy of the receptor) with
different concentrations of DA (Figure 4H), as was determined
experimentally in curve-shift experiments (Figure 2B).
To simulate the L94A mutant receptor, at which SV-III-130
did not display insurmountable antagonism, the estimates of
SV-III-130 kon and koff from our experiments with L94A D2R
were incorporated into a three-state binding model. Simulated
SV-III-130 inhibition curves demonstrated similarities between
the four-state (WT) and three-state model with parameters
from the L94A mutant D2R (Figure 4I). The simulated curves
support the notion that the irreversibly bound state contributes
very little to the Ki estimates derived from inhibition curve
experiments, which would be in agreement with our
experimental findings (see Figure 3G). The simulated response
recovery from SV-III-130 antagonism in the three-state model
(L94A mutant) was pronounced as compared to the four-state
model (WT), for both 1 and 100 μM DA (Figure 4J).
L94A Mutation Induces Conformational Changes in
the Receptor and Ligand Binding Mode of SV-III-130.
To study the impact of the L94A mutation on ligand binding
and receptor dynamics at the molecular level, we carried out
all-atomistic molecular dynamics simulations for the WT D2R
and the L94A mutant receptor in complex with SV-III-130
(Figure 5A). In the WT D2R, the orthosteric pharmacophore
of SV-III-130 is buried deeply in the orthosteric binding
pocket,16,19 whereas the secondary pharmacophore is primarily
stabilized by contacts with I184 in extracellular loop 2 and
W100 in extracellular loop 1 (shown as blue van der Waals
radii; Figure 5A). Upon L94A mutation (orange van der Waals
radii; Figure 5A), the ligand translates toward transmembrane
segment 2 (yellow arrow 2; Figure 5A) while maintaining
similar contact ratios with I184 and W100 compared to the
WT (contact ratioW100/I184: 1.17 [mutant] vs 1.20 [WT];
Figure 5C, D). Interestingly, the similar contact ratios correlate
well with the similar estimated affinities of SV-III-130 at the
WT and L94A mutant receptors (Figure 3G).
We found that L94A mutation creates an empty space
adjacent to transmembrane segment 2 which becomes
occupied by W100, enabling tight packing of W100 against
transmembrane segment 2 (Figure 5D). In contrast, the
bulkier L94 impedes such tight W100 packing in the WT
receptor (Figure 5C). This finding was supported by
computing the distribution of the distances between the Cα
atoms of W100 and L/A94 in transmembrane segment 2 over
the entire simulation time (distanceW100 to TM2), which revealed
significantly shorter distances in the L94A mutant compared to
the WT D2R (Figure 5B, left panel). As a result of the tight
W100 packing (Figure 5A; yellow arrow 1), SV-III-130
followed the movement of W100 (Figure 5A; yellow arrow
2) which in turn led to an adaption of extracellular loop 2
(Figure 5A; yellow arrow 3).
In addition to this, the distance plot of W100 to
transmembrane segment 2 (Figure 5B, left panel) suggests
that W100 in extracellular loop 1 is more flexible in the WT
D2R compared to the L94A mutant, as reflected by its wider
spatial distribution in the WT receptor. Among these
conformations, we observed receptor states with W100 buried
in the secondary binding pocket (Figure 5C) and con-
formations where W100 is exposed to the solvent forming a
“lid” on top of the ligand (Figure 5E, F). The location of W100
can be approximated by its position in the z dimension: a high
z value (approximately >22 Å) corresponds to the “lidlike”
conformations (Figure 5E, F), whereas a low z value
(approximately <22 Å) corresponds to conformations where
W100 is buried in the protein (Figure 5C). Interestingly, we
found that the “lidlike” conformations are only explored in the
WT receptor (Figure 5E, F) as highlighted by the box plot
(Figure 5B, right panel). It is tempting to speculate that such
conformations obstruct the ligand exit gateway, leading to a
conformation of the D2R-SV-III-130 complex which has a
significantly slower koff than the conformation presented in
Figure 5C. Indeed, this hypothesis is supported by recent
findings that L94 interacts with W100 and I184, forming a “lid”
over the secondary binding pocket in the risperidone-bound
D2R crystal structure, an interaction which influences ligand
residence time in radioligand binding experiments.13 A recent
study by Lane et al.30 likewise highlighted the role of L94 in
controlling the dynamics of W100 and also found evidence for
an important role of W100 in restricting ligand access to and
egress from the D2R orthosteric binding pocket. Similar
findings of ligand dissociation being restricted by a “lid”
formed by the extracellular loops have been reported for the
serotonin 5-HT2A receptor as well.
31
As described above, we directly tested the role of W100 by
mutagenesis, creating a W100A D2R mutant. The loss of SV-
III-130 affinity observed at this mutant (Figure 2 and Table 2)
is congruent with the molecular dynamics simulations
presented above, suggesting that W100 mediates important
stabilizing contacts between the secondary pharmacophore of
SV-III-130 and the receptor (Figure 5C, D). Notably, the rates
and extents of recovery from SV-III-130 inhibition were
increased at the W100A mutant, compared to WT D2R, both
when using 10 μM and 300 μM DA during the recovery phase
(Figure 3C−E). These findings are in agreement with our
hypothesis that W100 plays a crucial role in trapping SV-III-
130 in the WT D2R.
Surmountable and Insurmountable Behavior of
Antagonist Ligands in the GIRK Assay Is Recapitulated
upon Ligand Preapplication in a Beta-Arrestin Recruit-
ment Assay. Using a BRET assay in transfected HEK293
cells, full concentration−response curves for DA-induced beta-
arrestin2 recruitment to D2R were produced in the presence of
increasing concentrations of SWR-1-8, SV-III-130, and SWR-1-
14. Cells were preincubated with antagonist ligands for 5 min,
after which dopamine was added.
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Preincubation with SWR-1-8 or SWR-1-14 induced a
progressive right-shift of the concentration−response curve
for dopamine without affecting the maximum response
amplitude (Figure 6A, C), consistent with competitive
antagonism. On the other hand, the maximum effect of
dopamine was progressively diminished in the presence of
increasing concentrations of SV-III-130, while the EC50 of DA
remained virtually unchanged (Figure 6B), in agreement with
an insurmountable mode of antagonism.
Our study implies the existence of two distinct binding
modes of SV-III-130 at the D2R with the position of W100,
relative to the bound ligand, playing an important role in
creating these two states. The dynamics of W100 following
ligand binding is apparently slow enough to appreciate the
existence of two separate binding states. In agreement with the
considerable flexibility of W100 suggested by our molecular
dynamics simulations, the position of this residue differs
markedly between the risperidone- and the haloperidol-bound
D2R crystal structures.
13,27 Whereas W100 stacks on top of
risperidone, as noted above, the residue is rotated away from
the secondary binding pocket in the haloperidol-bound
structure.27 In future experiments, it will be interesting to
further study the role of W100 for the dissociation kinetics and
surmountabilities of risperidone and haloperidol. Moreover,
the finding that SV-III-130 behaves as an insurmountable
antagonist when investigated both in an assay of G protein-
dependent signaling (GIRK activation) and in an arrestin
recruitment assay may imply that the conformation of the
secondary binding pocket, or at least of W100, does not differ
markedly between G protein- and arrestin-coupled states of
D2R. This is particularly interesting given the suggested
implication of I184, which interacts with both SV-III-130 and
W100, in mediating agonist bias between G protein and
arrestin signaling.32
Our findings furthermore underscore how measures of
ligand potency and kinetics can be heavily influenced by
incubation time and order of ligand addition: In the curve-shift
GIRK experiments, SV-III-130 behaved as a classic competitive
agonist when the ligand was added simultaneously with DA,
whereas in recovery experiments with WT D2R, there was a
marked decrease in the ability of DA, even at 100 μM, to
activate the receptor following washout of SV-III-130 from the
extracellular medium. Interestingly, this decrease became even
more pronounced with longer intervals of application of SV-
III-130. We interpret this phenomenon as an example of
induced-fit binding.8
The proposed induced-fit binding mechanism of SV-III-130
may be relevant for understanding the long-lasting receptor
occupancy observed with clinical dosing of the structurally
similar weak partial agonist antipsychotic, aripiprazole.33 The
information beginning to be unraveled by the present study
may also benefit PET tracer development. Whereas [11C]-SV-
III-130 binding is displaced to some extent by amphetamine,21
certain other D2R PET tracers, such as [
11C]-(N-methyl)-
benperidol, show virtually no amphetamine-induced displace-
ment.34 A radiotracer’s receptor binding kinetics, as well as its
tissue-to-plasma efflux rate, has been suggested to affect
sensitivity to endogenous transmitter release,12 and the
reversibility of tracer binding would also seem to be important
for these characteristics. Thus, better knowledge of the
mechanisms responsible for induced-fit insurmountable bind-
ing could potentially enable the rational design of PET tracers
suitable for measuring D2R density vs endogenous DA release.
As with all heterologous expression systems, the Xenopus
oocyte system comes with several limitations. The oocytes do
not express the full complement of D2R-interacting proteins
found in native cells, such as medium spiny neurons of the
striatum. Furthermore, GIRK channel currents are an indirect
readout of GPCR occupancy by agonist. However, the GIRK
assay does allow for the study of dynamic processes with high
temporal resolution and without the need for receptor
modification. Importantly, we have previously shown that
our affinity estimates, derived either from IC50 values or from
estimates of kinetic rate constants, are in good agreement with
published data from radioligand binding studies.23 Finally, it
should also be noted that SV-III-130 binding could be almost
completely displaced by the D2/3R antagonist, eticlopride, in a
previous PET study,21 seemingly at odds with the irreversible
binding implied by our model. However, this displacement
took place over a longer time course (∼40 min) than studied
in our experiments, suggesting that the induced-fit binding of
SV-III-130 might be reversible on a longer time scale.
Moreover, the ability to compete with SV-III-130 bound in
the putative RL* state may be ligand-specific.
■ CONCLUSIONS
Our experimental and in silico findings support two distinct
binding modes of SV-III-130 at D2R, where the first binding
mode is competitive and surmountable by DA, whereas the
second, induced-fit binding mode is irreversible and hence
insurmountable. In particular, L94A mutation preserved SV-
III-130 potency but abolished its insurmountability. Molecular
dynamics simulations suggested that the L94A mutation might
Figure 6. Curve-shift beta-arrestin2 recruitment assay of D2R antagonism resulting from preapplication of SWR-1-8, SV-III-130, and SWR-1-14.
Curve-shift experiments for DA-induced beta-arrestin2 recruitment to D2R following 5 min preincubation with A) SWR-1-8, B) SV-III-130, and C)
SWR-1-14. The normalized data represent mean values from three independent experiments (n = 3) performed in triplicate. The curves represent
the best fit to the data using nonlinear regression analysis.
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perturb the positioning of W100 in extracellular loop 1 over
the ligand binding site, reducing the prevalence of “lidlike”
conformations where W100 stacks on top of the ligand,
preventing its egress. Thus, trapping by W100 may be the
structural mechanism for insurmountable antagonism by SV-
III-130. The present insights into the role of the secondary
binding pocket for induced-fit, irreversible binding at the D2R
may provide information for the prospective development of
improved therapeutic and radiotracer ligands.
■ METHODS
Molecular Biology. WT human dopamine D2L receptor (D2R)
cDNA was subcloned into pXOOM (provided by Dr. Søren-Peter
Olesen, University of Copenhagen, Denmark). Mutagenesis was
performed by Genscript Biotech (Piscataway, NJ). All mutations were
verified by sequencing. cDNA encoding human GIRK1 (Kir3.1),
GIRK4 (Kir3.4) (provided by Dr. Terence Hebert, University of
Montreal, Canada), and regulator of G protein signaling 4 (RGS4)
(from the Missouri cDNA Resource Center; www.cdna.org) were in
pCDNA3 (Invitrogen). Plasmids were linearized using the appro-
priate restriction enzymes (D2R, RGS4; XhoI and GIRK1/GIRK4;
NotI), followed by in vitro transcription using the T7 mMessage
mMachine kit (Ambion, Austin, TX). cRNA concentration and purity
were determined by spectrophotometry.
Oocyte Preparation. Oocytes from the African clawed toad,
Xenopus laevis, were isolated surgically as described previously.35 The
surgical procedures were approved by the Swedish National Board for
Laboratory Animals and the Stockholm Ethical Committee. Following
24-h incubation at 12 °C, oocytes were injected (using a Nanoject
microinjector; Drummond Scientific) with 0.2 ng of D2L receptor
cRNA, 40 ng of RGS4 cRNA, and 1 ng of each GIRK1 and GIRK4
cRNA in a volume of 50 nL per oocyte. RGS4 is a GTPase activating
protein and was included in order to speed up the kinetics of G
protein turnover, such that GIRK channel opening more closely
follows D2R occupancy by DA.
D2R Ligands. DA was purchased from Sigma-Aldrich (St. Louis,
MO). SWR-1-8, SWR-1-14, and SV-III-130 were synthesized as
previously described,15 dissolved in DMSO, and diluted in the
recording buffer to a maximum final DMSO concentration of 0.3% v/
v.
Electrophysiology Methods. Following incubation of oocytes
for 5−7 days at 12 °C, two-electrode voltage-clamp (CA-1, Dagan,
Minneapolis, MN) recordings were conducted at room temperature
(22 °C), as previously described.35 Data were acquired at a membrane
potential of −80 mV and 134 Hz sampling frequency using
pCLAMP8 (Molecular Devices, Sunnyvale, CA). To increase the
inward rectifier potassium channel current at negative potentials, a
high potassium concentration extracellular perfusion buffer was used
(in mM: 64 NaCl, 25 KCl, 0.8 MgCl2, 0.4 CaCl2, 15 HEPES, 1
ascorbic acid, adjusted to pH 7.4), yielding a K+ reversal potential of
about −40 mV. Ascorbic acid was used to prevent the spontaneous
oxidation of DA. Oocytes were perfused with solutions at a rate of 1.5
mL/min using the pressure-driven, computer-controlled SmartSquirt
system (Automate Scientific, Berkeley, CA).
Gel Electrophoresis and Immunoblotting. Striata from WT
and D2R knockout mice (tissue from an earlier study; Taura et al.,
201829) or frozen injected oocytes were homogenized in ice-cold 50
mM Tris HCl buffer (pH 7.4) containing a protease inhibitor cocktail
(Roche Molecular Systems, Pleasanton, CA) using a Polytron for
three periods of 10 s each. The homogenate was centrifuged for 10
min at 1000g. The resulting supernatant was centrifuged for 30 min at
12000g to pellet total membranes. The oocyte total membrane
fractions were solubilized in 1% Triton X-100 to eliminate a major
contaminating band of equivalent molecular mass that alters the
normal migration of D2R.
36
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) was performed using 10% polyacrylamide gels. Proteins were
transferred to a Hybond-LFP polyvinylidene difluoride (PVDF)
membrane (GE Healthcare, Chicago, IL) using a Trans-Blot SD
Semi-Dry Transfer Cell (Bio-Rad, Hercules, CA). The PVDF
membrane was blocked with 5% (w/v) dry nonfat milk in
phosphate-buffered saline containing 0.05% Tween-20 (PBS-T) for
45 min and immunoblotted using rabbit polyclonal anti-D2R (1 μg/
mL; Frontier Institute Co. Ltd., Ishikari City, Japan) antibody in a
blocking solution overnight at 4 °C. The PVDF membrane was then
washed with PBS-T three times (5 min each) before incubation with
horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (1/
30,000; Pierce Biotechnology, Rockford, IL) in a blocking solution at
20 °C during 2 h. After washing the PVDF membranes with PBS-T
three times (5 min each), the immunoreactive bands were developed
using a chemiluminescent detection kit (Thermo Fisher Scientific,
Waltham, MA) and detected with an Amersham Imager 600 (GE
Healthcare Europe GmbH, Barcelona, Spain). Subsequently, the
PVDF membrane was also immunoblotted with rabbit polyclonal
anti-β-tubulin-HRP (0.16 μg/mL; ab21058, Abcam, Cambridge, UK)
for protein loading control.
Cell Culture. Cell culture reagents and selection antibiotics were
purchased from LifeTechologies/Invitrogen (Grand Island, NY). The
D2 BRET cell line was constructed as indicated below. All other
buffers and compounds were purchased from Sigma-Aldrich (St
Louis, MO), unless specified otherwise. Stable D2-Rluc8 − Arrestin-
Venus cells (D2-BRET-Arr) were created by doubly transfecting Flp-
In T-REx 293 HEK cells (Invitrogen, Carlsbad, CA) with a beta-
arrestin-2-mVenus acceptor vector expressed constitutively and a D2
DAR-Rluc8 donor vector under control of a tetracycline inducible
promoter. In this way, the expression of the D2 DAR can be induced
and thus the receptor-donor/arrestin expression ratio controlled. D2-
BRET-Arr cells were cultured in Dulbecco’s modified Eagle’s Medium
containing 10% FBS, 1000 units/mL penicillin, 1000 μg/mL
streptomycin, 100 mM sodium pyruvate, 1 μg/mL gentamicin, 2
μg/mL puromycin, and 100 μg/mL hygromycin.
Beta-Arrestin Recruitment Assay. Direct protein−protein
interaction between D2R and beta-arrestin2 was analyzed using
BRET assays where the interaction of the receptor (donor) with beta-
arrestin2 (acceptor) results in a shift of the emission spectra of the
Rluc8 tag (after incubation with coelenterazine-h) from 485 to 525
nm as previously described by our laboratory.37 The resulting
luminescence was read and quantified on a Flexstation III multiplate
reader (Molecular Devices, San Jose, CA). Results were expressed as a
normalized ratio of emission observed with control agonist alone.
Since the BRET signal is dependent on the donor/acceptor
expression ratio, this must be optimized in order to achieve the
best response by varying the expression level of the Rluc8-tagged
receptor. D2-BRET-Arr cells were seeded at 3 × 10
6 cells/144 mm
dish in culture media without puromycin or hygromycin selection.
Adherent cells were then incubated with 40 nM tetracycline added
directly to the culture media to induce D2R expression. The cells were
then incubated for 24 h at 37 °C in 5% CO2 and 90% humidity.
Following incubation, cells were centrifuged at 1000g for 10 min and
resuspended (200,000 cells/mL) in Dulbecco’s Phosphate Buffered
Saline containing 0.01% sucrose. Cells were dispensed into solid-
bottom white 96-well plates (Greiner Bio-one, Monroe, NC) at 100
μL/well (20,000 cells/well) and incubated at room temperature for
45 min. Following incubation, cells were incubated for 5 min with 5
μM coelenterazine h (Nanolight Technology, Pinetop, AZ) in the
dark. Cells were then stimulated with the appropriately diluted agonist
for 5 min prior to reading. For antagonist assays, a test compound was
added to the cells and incubated for 5 min prior to agonist addition.
Concentration−Response Data Analysis. Electrophysiological
data were analyzed using Clampfit (Molecular Devices). Concen-
tration−response curves were calculated using the variable-slope
sigmoidal functions in GraphPad 5. For IC50 estimation, 100 nM DA
was applied to an oocyte to provide a baseline response, followed by
increasing concentrations of antagonist applied with 100-s intervals
(for SWR-1-8 and SWR-1-14, 50-s intervals were used, as their
relatively rapid kinetics allowed for faster equilibration). For each cell,
the response amplitude at the end of each antagonist application
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interval was normalized to the current elicited by 100 nM DA at the
beginning of the protocol. Data were fitted to the equation
Y bottom
1
1 10 X( log IC )10 50
= +
+ −
where Y is the response as a fraction of 1, bottom is the maximal
response inhibition evoked by the antagonist, and X is the logarithm
of ligand concentration.
For DA potency data, increasing concentrations of DA were
applied at 25-s intervals, and the response amplitudes achieved with
each concentration normalized to the response evoked by 100 μM
DA. The equation used for fitting agonist data was
Y
1
1 10 X EC( log )10 50
=
+ − −
Intrinsic efficacy of the ligands was evaluated by a 100 s application
and normalization to the response of 1 μM DA in the same oocyte.38
Data points were represented as mean ± SEM.
For curve-shift experiments, a maximal response was first evoked by
application of 1 μM DA, which was subsequently washed out,
followed by the application of DA in the presence (or absence, to
generate the control curve for DA alone) of different concentrations
of SV-III-130. The current amplitude following 500 s of coapplication
of DA and SV-III-130 was normalized to the initial response elicited
by 1 μM DA.
Estimation of Rate Constants. Association rate constants, kon,
were calculated based on the observed association rate, kobs, in









where the antagonist concentration is known, and the fraction of
unoccupied receptors, R0, prior to antagonist application is derived
from the concentration−response curve of DA at D2R. Specifically, R0
for 100 nM DA at the WT D2R was estimated as 0.30 (Figure 1B). koff
was estimated separately as
k tln(2)/off 1/2=
where t1/2 is the time for half-maximal response recovery.
Ligand affinity estimates based on binding kinetics were calculated
as
k k k/d off on=
Receptor Binding Models. Recovery from D2R antagonism was
modeled as a three-state process, using experimental values for kon and
koff. The three states capturing competitive binding were unbound
receptor (R), agonist-bound receptor (RA), and ligand-bound
receptor (RL)
where kon and koff are association and dissociation rate
constants for the competing ligand (L) and the agonist DA
(A). The induced-fit ligand binding was modeled as
where RL* denotes the ligand bound to the induced-fit state of
the receptor, and k2 is the association rate of the ligand to the
RL* state.
Derivation of Kinetic Parameters. Based on the previously
described t1/2 for D2R-induced GIRK response termination (in the
presence of RGS4) upon DA washout,39 the agonist dissociation rate
koff(A) was approximated to 0.17/s. The association rate constant kon(A)
was calculated from the experimental DA EC50: koff/EC50 = kon = 5 ×
106 M−1 s−1. For the induced-fit model (eq 2), a constant, irreversible
flux kon(RL*) from RL to RL* was selected with a time constant of 100
s to recapitulate the features of the response recovery experiments.
Molecular Dynamics Simulations. Molecular dynamics simu-
lations have been proven valuable for shedding light on molecular
mechanisms underlying ligand binding and GPCR functionality.40−42
To generate the D2R-SV-III-130 WT complex, we utilized the crystal
structure of the D2R (PDB code: 6CM4). The ligand was docked into
the D2R structure using the standard docking protocol from MOE
(www.chemcomp.com). The final docking pose was selected based on
scoring and visual inspection. The generated WT complex was aligned
to the membrane using the OPM database,43 placed in a POPC
membrane, and solvated with TIP3 waters, using the CHARMM-GUI
server.44 The ionic strength of the system was kept at 0.15 M using
NaCl ions. The L94A system was generated by introducing the
mutation using the CHARMM-GUI pipeline.
Simulations were carried out similarly to previously published
protocols45−47 using the ACEMD simulation package.48 Ligand
parameters were assigned by ParamChem from the CGenFF force
field.49,50 Parameters for other system components were obtained
from CHARMM36m51 and CHARMM36 force fields.52 In the
simulation protocol, we adhere to the guidelines of the GPCRmd
consortium.53
The systems were first relaxed during 200 ns of simulations under
constant pressure and temperature (NPT) with a time step of 2 fs,
with gradually decreasing harmonic constraints applied to the protein
backbone. Temperature was maintained at 310 K using the Langevin
thermostat,54 and pressure was kept at 1 bar using the Berendsen
barostat.55 The equilibration run was followed by four 800 ns
production runs under constant volume and temperature (NVT) with
a 4 fs time step. This allowed us to amass a complete simulation time
of 3.2 μs for the WT and L94A systems, respectively. The temperature
was maintained at 310 K using the Langevin thermostat. No harmonic
constraints are applied in the NVT phase. In all simulations, we used
van der Waals and short-range electrostatic interactions with a cutoff
of 9 Å and the particle mesh Ewald method56 for long-range
electrostatic interactions.
Ligand−receptor contacts were quantified using the “get_contacts”
script.57 The computed ratio of W100 and I184 contacts was
quantified by dividing the stability of W100 contacts by I184 contacts.
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